| 000 | 01345 a2200409 4500 | ||
|---|---|---|---|
| 005 | 20250515231142.0 | ||
| 264 | 0 | _c20110602 | |
| 008 | 201106s 0 0 eng d | ||
| 022 | _a1463-1326 | ||
| 024 | 7 |
_a10.1111/j.1463-1326.2010.01225.x _2doi |
|
| 040 |
_aNLM _beng _cNLM |
||
| 100 | 1 | _aAubert, R E | |
| 245 | 0 | 0 |
_aRosiglitazone and pioglitazone increase fracture risk in women and men with type 2 diabetes. _h[electronic resource] |
| 260 |
_bDiabetes, obesity & metabolism _cAug 2010 |
||
| 300 |
_a716-21 p. _bdigital |
||
| 500 | _aPublication Type: Journal Article | ||
| 650 | 0 | 4 | _aAdult |
| 650 | 0 | 4 |
_aDiabetes Mellitus, Type 2 _xcomplications |
| 650 | 0 | 4 | _aFemale |
| 650 | 0 | 4 |
_aFractures, Bone _xchemically induced |
| 650 | 0 | 4 | _aHumans |
| 650 | 0 | 4 |
_aHypoglycemic Agents _xadverse effects |
| 650 | 0 | 4 | _aIncidence |
| 650 | 0 | 4 | _aMale |
| 650 | 0 | 4 | _aMiddle Aged |
| 650 | 0 | 4 | _aPioglitazone |
| 650 | 0 | 4 | _aRisk Factors |
| 650 | 0 | 4 | _aRosiglitazone |
| 650 | 0 | 4 |
_aThiazolidinediones _xadverse effects |
| 650 | 0 | 4 | _aTreatment Outcome |
| 700 | 1 | _aHerrera, V | |
| 700 | 1 | _aChen, W | |
| 700 | 1 | _aHaffner, S M | |
| 700 | 1 | _aPendergrass, M | |
| 773 | 0 |
_tDiabetes, obesity & metabolism _gvol. 12 _gno. 8 _gp. 716-21 |
|
| 856 | 4 | 0 |
_uhttps://doi.org/10.1111/j.1463-1326.2010.01225.x _zAvailable from publisher's website |
| 999 |
_c19937985 _d19937985 |
||